Previously, we showed that the BRCA1 protein interacts directly and functionally with estrogen receptor-alpha (ER-a), resulting in the inhibition of estradiol (E2)-stimulated ER-a transcriptional activity. The interaction sites were mapped to the N-terminus of BRCA1 (within amino acids (aa) 1-302) and the ligand-binding domain/ activation function-2 (LBD/AF-2) region (within aa 282-420) of ER-a. In this study, we have further characterized the structure/function relationship for the BRCA1 : ER-a interaction. We found that the N-terminal RING domain (aa 20-64) is not required for the BRCA1 : ER-a interaction. We identified two separate contact points for ER-a, one within aa 1-100 and the other within aa 100-200 of BRCA1; and we showed that each of these BRCA1 peptides interacts with BRCA1 in vitro and in vivo. By using different fragments of the BRCA1 Nterminus, we found that aa 67-100 and 101-133 are required for the interaction with ER-a, but that aa 1-67 and 134-302 are dispensible. Previously, we showed that BRCA1 aa 1-302 does not inhibit E2-stimulated ER-a transcriptional activity but does bind to ER-a and acts as a dominant negative inhibitor of the full-length BRCA1 protein. Somewhat surprisingly, we found that BRCA1 aa 1-100 and BRCA1 aa 101-200 (but not aa 201-300) each inhibited ER-a activity, although not as efficiently as fulllength BRCA1. Mutations within an HIV Rev-like nuclear export signal that resembles a nuclear receptor corepressor motif (aa 86-95) impaired the ability of both truncated (aa 1-100) and full-length (aa 1-1863) BRCA1 proteins to interact with and/or repress ER-a activity. Based on these findings, a partial BRCA1 : ER-a threedimensional structure is proposed. The implications of these findings for understanding the BRCA1 : ER-a interaction are discussed.
Introduction
The breast cancer susceptibility gene 1 (BRCA1) on human chromosome 17q21 was identified and cloned by Miki et al. (1994) . Inherited mutations of this gene confer a high risk for breast and/or ovarian cancer. Members of BRCA1 mutation families also exhibit significantly increased risks for several other hormoneresponsive cancer types, including endometrial and cervical cancers in women and prostate cancer, particularly in men younger than age 65 years (Ford et al., 1994; Thompson and Easton, 2002) . These findings suggest an increased propensity to develop steroid hormone-responsive cancer types in BRCA1 mutation carriers. While most research on BRCA1 molecular functions has centered on its roles in DNA damage signaling and repair and the regulation of cell cycle progression, the ability of BRCA1 to modulate hormonal response pathways is now well documented (reviewed by Rosen et al., 2003) .
Some of the tumor suppressor activity of BRCA1 is through to be due to its function as 'caretaker' gene to protect the genome and maintain genomic stability. Thus, BRCA1 is required for several cell cycle checkpoints, including the DNA damage-responsive intra-S and G2/M checkpoints and the G2 decatenation checkpoint (Xu et al., 1999 (Xu et al., , 2001 Deming et al., 2001) . BRCA1 also participates in double-strand DNA break repair, homologous recombination, Fanconi-type repair, and other DNA repair pathways; and BRCA1 is a phosporylation target for the nuclear DNA damage signaling kinases ATM (ataxia-telangiectasia mutated) and ATR (ATM and Rad3 related) (reviewed in Rosen et al., 2003) . Although these findings suggest how BRCA1 may function as a tumor suppressor, they do not explain the association of BRCA1 mutations with estrogen-responsive tumor types, such as breast and endometrial cancers. This association is further supported by the finding that prophylactic oophorectomy protects against the development of breast cancer in women with inherited mutations of BRCA1 (Narod, 2001; Rebbeck et al., 2002) . These conditions suggest that in addition to its role(s) in protecting the genome, BRCA1 has tissue-specific or selective actions.
Several years back, we showed that BRCA1 inhibits estrogen (E2)-stimulated estrogen receptor (ER-a) activity (Fan et al., 1999) . This inhibition is due, in part, to a direct interaction between the BRCA1 and ER-a proteins and, in part, to downregulation of expression of a transcriptional coactivator for ER-a, p300 (Fan et al., 2001a (Fan et al., , 2002 . It was also demonstrated that BRCA1 mediates ligand-independent repression of ER-a (i.e., prevents the activation of the receptor in the absence of E2) and inhibits the E2-inducible secretion of vascular endothelial growth factor (VEGF) (Zheng et al., 2001; Kawai et al., 2002) . Exogenous BRCA1 inhibited the E2-inducible expression of two endogenous E2-responsive genes, pS2 (trefoil factor) and cathepsin D (Fan et al., 2001a) .
Previous studies have established a direct interaction between the N-terminus of BRCA1 (amino acid (aa) 1-302) and the C-terminus (aa 282-420 and 393-595) of ER-a (Fan et al., 2001a; Kawai et al., 2002) . Here, we have performed higher resolution mapping of the BRCA1 : ER-a interaction; we have investigated the structural determinants for the physical interaction and its functional consequences (i.e., repression of ER-a activity by BRCA1). These findings provide new insight into the nature of the BRCA1 : ER-a interaction and its consequences.
Results

High-resolution mapping of BRCA1 : ER-a interaction
Previously, we identified binding sites for ER-a within the N-terminus of BRCA1 (aa 1-302) and the C-terminus of . Here, we utilized GST capture assays to further refine the binding regions on these two proteins. We constructed a series of BRCA1 expression vectors in the pCMV-Tag2 vector corresponding to portions of the N-terminus within aa 1-302 ( Figure 1a ). This vector allows in vitro transcription of BRCA1 proteins as well as in vivo expression in mammalian cells with an N-terminal FLAG epitope tag (Fan et al., 2001b) . These expression vectors were utilized to generate a series of 35 Smethionine-labeled in vitro transcribed and translated (IVT) BRCA1 proteins ( Figure 1b) . Initially, these IVT proteins were tested for binding to beads coated with GST alone (negative control) (Figure 1c ) or GST-ER 282-420 (Figure 1d and e), with the following results:
Bound to Did not bind to Bound to GST alone: none Taken together, these findings suggest the presence of at least two contact points for ER-a on BRCA1, one within aa 67-100 and the other within aa 101-133. Interestingly, these results indicate that that the conserved N-terminal RING domain of BRCA1 (aa 24-64) is not required for interaction with ER-a, since BRCA1 proteins with the RING domain missing (aa 67-302) or disrupted (aa 34-302) were captured by GST-ER 282-420. The current finding is consistent with our previous study indicating that a full-length tumor-associated BRCA1 mutant (T300G ( 61 Cys-Gly)) did not disrupt the binding to ER-a (Fan et al., 2001a) . However, the BRCA1-T300G protein failed to repress ER-a activity, indicating that an intact RING domain is required for inhibition of ER-a activity by the full-length BRCA1 protein (Fan et al., 2001a) .
Next, we sought to further delimit the binding site(s) for BRCA1 on the ER-a protein.
To start off, we tested the ability of a series of GST-ER proteins (Figure 2a and b) to capture a portion of BRCA1 containing both ER-a contact points (BRCA1 1-302). These studies revealed that most of the BRCA1 : ER-a interaction was mediated by aa 338-379 of ER-a; but a smaller amount of binding could be ascribed to aa 420-595 of ER-a ( Figure 2c ). As negative controls, GST alone failed to capture IVT BRCA1 1-302 ( Figure 2c) ; while neither GST only nor any of the series of GST-ER proteins captured IVT BRCA1 303-1863, which, in our hands, does not bind ER-a (Figure 2d ).
These findings indicated that the ER-a protein contains at least two contact points for BRCA1: (1) aa 338-379 and (2) aa 420-595. These sites are located within the activation factor-2 (AF-2)/ligand-binding domain (LBD) (E) and cofactor-binding domain (F) regions of ER-a. Next, we examined the ability of GST-ER 338-379 and GST-ER 420-595 to capture smaller BRCA1 proteins within aa 1-302. Here, we noted that GST-ER 338-379 captured both BRCA1 1-100 and BRCA1 101-200; while GST-ER 420-595 captured BRCA1 1-100 but not BRCA1 101-200 (Figure 2e and f). Our previous studies suggest that the interaction between the full-length BRCA1 and ER-a proteins in vivo occurs independently of E2 (Fan et al., 2001a) . Here, we ascertained the ability of different GST-ER proteins to capture an N-terminal BRCA1 protein containing both ER-a interaction sites (BRCA1 1-302). We found that in the presence of E2, there was a modest reduction in binding of BRCA1 1-302 to GST-ER 338-379 and to GST-ER 420-595; however, in both cases, significant binding was retained (Figure 2g ).
BRCA1 : ER-a interaction in vivo
Previously, we showed that the full-length BRCA1 and ER-a proteins associate with each other in vivo in the absence or presence of estrogen (Fan et al., 2001a (Fan et al., , 2002 . Here, we performed immunoprecipitation (IP)-Western blotting assays to determine if ER-a binding BRCA1 protein fragments identified above associate with the endogenous ER-a protein in MCF-7 cells. MCF-7 cells were transfected with FLAG-tagged BRCA1 proteins encompassing aa 1-100, 101-200, and 201-300. Each of the FLAG-BRCA1 proteins was expressed well. Consistent with the GST capture assays, we found that IP of FLAG-BRCA1 1-100 and 101-200, but not 201-300, co-precipitated ER-a ( Figure 3a ) and vice versa ( Figure 3b ). As observed in the GST capture assays, the interaction of ER-a with BRCA1 1-100 appeared to The bars show the ratios of bound to input BRCA1 proteins derived from a densitometric analysis of the data from panel (e). (g) Effect of estrogen (E2) on BRCA1 binding to different GST-ER proteins. Beads coated with different GST-ER proteins were incubated with IVT BRCA1 1-100 in the absence or presence of 17b-estradiol ( þ E2, 1 mM) and tested for capture of BRCA1 1-100. Values are expressed as a percent of BRCA1 1-100 captured by GST-ER 338-379 in the absence of E2. Note: In all cases in these other figures, the IVT input lanes show 10% of the protein used in the GST capture assays be stronger than that with BRCA1 101-200, suggesting that the former contains the primary interaction site.
Our previous studies suggested a model in which the N-terminus of BRCA1 (aa 1-302) interacts with ER-a, while the C-terminus executes the transcriptional repression function (Fan et al., 2001a) . This model was suggested by the findings that the BRCA1 1-302 protein (and several longer C-terminal-truncated BRCA1 proteins) failed to repress ER-a but 'rescued' (i.e., reversed) the repression caused by the full-length wild-type BRCA1 (wtBRCA1) protein (Fan et al., 2001a, b) . Here, we tested the ability of different BRCA1 protein fragments to inhibit the estradiol (E2)-stimulated ER-a activity, using the ERE-TK-Luc reporter, as described earlier (Fan et al., 1999) . These assays were carried out in an ER-negative cell line (DU-145) transfected with a wild-type ER-a expression vector. Both FLAG-BRCA1 1-100 and 101-200 significantly inhibited ER-a activity; however, neither protein was as effective as the fulllength wtBRCA1 in inhibiting ER-a activity (Figure 4a) . Furthermore, the combination of BRCA1 1À100 þ 101À200 ( þ 201À300) still did not repress ER-a activity as effectively as full-length wtBRCA1, suggesting that regions of BRCA1 outside of the N-terminus are required for maximal inhibition of ER-a. As negative controls, neither FLAG-BRCA1 201-300, nor the empty wtBRCA1 vector (pcDNA3), nor the empty FLAG vector (pCMV-Tag2) inhibited ER-a activity. In another experiment, we tested the ability of BRCA1 1-302 to rescue the inhibition of ER-a by BRCA1 protein fragments as it did for full-length wtBRCA1 (Fan et al., 2001a, b) . Consistent with previous findings, BRCA1 1-302 did not inhibit ER-a activity but did rescue the inhibition by full-length wtBRCA1 (Figure 4b ). Here, BRCA1 1-302 rescued the repression of ER-a by BRCA1 1-100 and by BRCA1 101-200 (Figure 4b ), suggesting that the recruitment of aa 201-300 (which does not independently bind) to ERa is required for rescue of the repression of ER-a activity (see Discussion).
Role of BRCA1 nuclear export signal (NES)/ corepressor-like motif in BRCA1 : ER-a interaction
Recently, it was shown that BRCA1 contains a functional HIV Rev-like NES within its N-terminus (aa 86-95) (Rodriguez and Henderson, 2000; Rodriguez et al., 2004 ) (see Table 1 ). This region of BRCA1 also contains a corepressor extended helix-like motif, LxxI(I/ H)xxx(I/L) (Perissi et al., 1999) . Since this motif is linked to inhibitory interactions between corepressors and nuclear receptors, we sought to examine its role in the BRCA1 : ER-a inhibitory interaction. The entire human BRCA1 leucine/isoleucine-rich region from aa 86 to95 showed a high degree of evolutionary conservation down to the mouse, with nonconservative substitutions observed in only a single noncritical residue (cysteine-91) (Table 1) . Based on these considerations, we prepared BRCA1 1-100 mutant cDNAs in the pCMV-Tag2 vector suitable for IVT or expression in mammalian cells, with one or more substitutions of alanine for leucine or isoleucine (see Table 1 ).
First, we compared the ability of different BRCA1 mutants to interact with ER 282-420 using GST capture assays. Each mutant BRCA1 1-100 protein expressed as well as the wild-type BRCA1 1-100 (Figure 5a and b). However, in three separate experiments, the binding of BRCA1 mutant 1 to GST-ER 282-420 was significantly less than that of BRCA1 mutant 2, mutant 3, or wildtype protein (Figure 5c and d). Mutant 1 (which contains three leucine or isoleucine to alanine substitutions) yielded about 28% of the wild-type control binding; whereas mutants 2 and 3 (which contain one or two leucine/isoleucine to alanine substitutions) exhibited 80-90% of control binding.
Next, we compared the ability of mutant vs wild-type BRCA1 1-100 proteins to repress E2-stimulated ER-a activity. As observed earlier, the wtBRCA1 1-100 inhibited ER-a activity significantly, but not as completely as the full-length wtBRCA1 protein ( Figure 6a ). Consistent with the GST capture assays, mutant 1, which showed greatly reduced binding to ER-a, lost most (or nearly all) of its ability to inhibit ER-a activity ( Figure 6a ). In contrast, mutants 2 and 3, which retained most of the binding activity, also retained the ability to repress ER-a activity. 
We tested the ability of the mutant BRCA1 1-100 proteins to rescue the inhibition of ER-a activity by the full-length wtBRCA1. Here, we found that each of the mutant BRCA1 proteins partially 'rescued' (reduced the degree of repression of the full-length wtBRCA1) the inhibition of ER-a ( Figure 6b ). This observation may reflect interference with the binding of the full-length BRCA1 to ER-a and/or interference with other protein interactions required for wtBRCA1-mediated repression of ER-a activity. Unlike BRCA1 1-302, none of the truncated and/or mutant BRCA1 proteins fully rescued the BRCA1 inhibition of ER-a. The lack of complete rescue of ER-a activity may owe to two factors: (1) some of these mutant proteins themselves have ER-a repression activity (although less than full-length wtBRCA1); and (2) presumably, the full-length wtBRCA1 protein can bind to and repress ER-a independently of any of the BRCA1 1-100 proteins via a second site within aa 101-200.
The mechanism(s) by which smaller BRCA1 proteins that do not contain a classical nuclear localization signal (NLS) has not been determined. Previously, we showed that BRCA1 1-302 enters the nucleus efficiently, even though it is missing the BRCA1 NLS (aa 501-507) (Fan et al., 2001b) . Here, we compared the ability of the FLAG-tagged BRCA1 1-100 wild-type and mutant proteins to enter the nucleus in MCF-7 cells, to determine if the inability of BRCA1 1-100 mutant 1 to repress ER-a activity could be due to inability to localize in the nucleus. We found that all of the BRCA1 1-100 proteins, including mutant 1, showed appropriate nuclear localization, although there was some perinuclear (? cytoplasmic) staining. There did not appear to be any obvious differences in the subcellular localization of these proteins (Figure 7) .
Having previously shown that the wild-type FLAG-BRCA1 1-100 protein interacts with ER-a in vivo in MCF-7 cells, we tested the ability of the mutant FLAG-BRCA1 1-100 proteins to associate with ER-a in vivo, by IP-Western blotting (Figure 8 ). The IP-Western blotting assays revealed that (1) BRCA1 1-100 (wildtype) and all three mutants were well expressed in MCF-7 cells; (2) an anti-FLAG IP of cells transfected with FLAG-BRCA1 mutant 1 brought down reduced Figure 7 Nuclear localization of BRCA1 1-100 mutant proteins. Subconfluent proliferating MCF-7 cells were transfected with expression vectors for FLAG-tagged BRCA1 1-100 wild-type and mutant proteins or with empty pCMV-Tag2 vector overnight, and postincubated for 24 h to allow gene expression. The cells were then stained with DAPI (to stain the nuclei) and anti-FLAG (to detect the FLAG-tagged BRCA1 proteins) and subjected to immunofluorescence microscopy Structure of BRCA1 : estrogen receptor interaction YX Ma et al quantities of ER-a, as compared with FLAG IPs of the other BRCA1 1-100 proteins ( Figure 8a ); and (3) and anti-ER-a IP co-precipitated smaller smaller quantities of the FLAG-BRCA1 1-100 mutant 1 than any of the other BRCA1 1-100 proteins (Figure 8b ). These findings suggest that the loss of the ability of BRCA1 1-100 mutant 1 to repress ER-a is due mostly to a loss of its ability to associate with and bind ER-a. Rodriguez and Henderson (2000) described a fulllength mutant BRCA1 protein with two amino-acid substitutions (a leucine and an isoleucine to alanine) that functionally inactivated the NES (see Table 1 ). We tested the ability of this full-length BRCA1-NES mutant protein to inhibit ER-a activity. Whereas the full-length wild-type BRCA1 protein fully repressed ER-a activity, the BRCA1-NES mutant protein completely failed to repress ER-a activity (Figure 9a ). Although it failed to inhibit ER-a, the BRCA1-NES mutant effectively rescued the repression by wtBRCA1. These findings suggest that mutations within BRCA1 aa 86-95 affect its ability to both bind and repress ER-a activity. The inability of the BRCA1-NES mutant protein to repress ER-a activity could not be due to inability to enter the nucleus. In fact, this mutation confers increased nuclear retention of the protein (Rodriguez and Henderson, 2000) . Nor could its inability to repress ER-a be due to inadequate levels of expression, since Western blotting revealed that the NES mutant and wtBRCA1 proteins are similarly well expressed in MCF-7 cells (Figure 9b) .
To determine if the NES mutation alters the in vivo interaction of BRCA1 and ER-a, we performed IPWestern blotting assays in HCC1937, a human breast cancer cell line that lacks endogenous function BRCA1. (These cells contain a single mutant BRCA1 allele (5382insC) (Tomlinson et al., 1998) .) The cells were cotransfected with BRCA1 and ER-a expression vectors, since they lack endogenous ER-a. The BRCA1-NES mutant and wtBRCA1 proteins were equally well expressed (Figure 9c) . However, the amount of ER-a precipitated by anti-BRCA1 and the amount of BRCA1 precipitated by anti-ER-a were significantly lower for BRCA1-NES mutant than for wtBRCA1 (Figure 9d and e, respectively), suggesting that the NES mutation weakens the in vivo association of BRCA1 and ER-a.
To further investigate the role of the NES/extended helix-like motif of BRCA1 within the context of the fulllength protein, we prepared expression vectors containing mutants 1, 2, and 3 (see Table 1 ), by site-directed mutagenesis of the full-length BRCA1 (1-1863) within the pcDNA3 plasmid. When transfected into DU-145 cells (which express low levels of endogenous BRCA1) or HCC1937 cells (which lack functional BRCA1), BRCA1 1-1863 mutant 1 gave or did not inhibition of ER-a activity (Figure 10a and b, respectively) . In contrast, BRCA1 1-1863 mutants 2 and 3 gave strong repression of ER-a activity, although neither mutant was as effective as full-length wtBRCA1. Under conditions similar to those used in the ER-a transcriptional assays, all of the mutants were expressed as well as exogenous wtBRCA1 in both cell types (see Figure 10c and d).
Consistent with the ER-a repression assays, IPWestern blotting of HCC1937 cells showed a significantly reduced steady-state association of BRCA1 1-1863 mutant 1 with ER-a, as compared with that of wtBRCA1, mutant 2, or mutant 3 (Figure 10e and f) . Finally, GST capture assays revealed a significant reduction in the amount of IVT BRCA1 1-1863 mutant 1 pulled down by GST ER 282-420 as compared with IVT wtBRCA1, BRCA1 1-1863 mutant 2, or BRCA1 1-1863 mutant 3 (Figure 10g ). These findings indicate that the presence of mutation 1 within the full-length protein inactivates the ability of BRCA1 to repress ER-a Figure 8 In vivo association of BRCA1 1-100 mutant proteins with ER-a. Subconfluent proliferating MCF-7 cells were transiently transfected with each of four FLAG-BRCA1 1-100 expression vectors or the empty pCMV-Tag2 vector, washed, postincubated for 24 h to allow gene expression, and harvested for IP using anti-FLAG (a) or anti-ER-a (b) antibodies. The precipitated proteins were immunoblotted to detect the exogenous FLAG-BRCA1 and endogenous ER-a proteins Structure of BRCA1 : estrogen receptor interaction YX Ma et al activity and substantially weakens its in vivo association and physical interaction with the ER-a protein.
Molecular modeling of the BRCA1 : ER-a interaction
Based on the findings of this study and on published studies of the structure of the BRCA1 N-terminus, aa 1-103 (Brzovic et al., 2001) , and the LBD of ER-a (Tanenbaum et al., 1998) , we have determined a preliminary and partial BRCA1 : ER-a complex structure (see Figure 11) . The complex structure of ER-a and BRCA1 was calculated using the Global Range Molecular Matching (GRAMM) program (v. 1.03) (Katchalski-Katzir et al., 1992) based on the published coordinates of ER-a (Tanenbaum et al., 1998) and BRCA1 (Brzovic et al., 2001) . The ER-a structure (c-e) In vivo association of BRCA1-NES mutant vs wtBRCA1 in HCC1937 human breast cancer cells. Cells were transfected with the indicated vector(s), postincubated for 24 h, and subjected to (c) Western blotting to determine protein expression levels; and (d-e) IPWestern blotting to determine the ability of each BRCA1 to associate with exogenous ER-a. In (d) and (e), the quantitative extent of association of BRCA1-NES mutant with ER-a was assessed by densitometry and expressed as a percentage of that of wtBRCA1 as means7s.e.m.'s from N ¼ 3 independent experiments Structure of BRCA1 : estrogen receptor interaction YX Ma et al covers residues 306-544, in which the residues 338-379 are identified as a key segment in the interaction with BRCA1 (highlighted in red in Figure 11 ). In this model, BRCA1 heterodimerizes with ER-a through the antiparallel a-helix domain, mainly through the third helix (aa 80-96) of BRCA1 (Figure 11a and b) . The ER-a side of the heterodimerization interface is the a-helix of ER-a (aa 338-379), which is at the opposite side of the ER-a homodimerization interface. Residues 420-595 of ER-a also have a small contact with the RING domain of BRCA1. This structure represents one of several low-energy arrangements of the complex, the one which best fits with the experiment results described above. It needs to be validated experimentally.
Some of the tumor mutations in BRCA1 (Brzovic et al., 2001 ) such as L63F and I89T are at the intermolecular interface (Figure 11b ). These mutations may weaken or otherwise alter the association of the two proteins and release ER-a from the inhibitory action of BRCA1. To test this possibility, we generated expression plasmids encoding full-length BRCA1 protein with either the L63F or I89T point mutations. Like point mutations 1 and 2 within the NES motif, these mutations retained binding to ER-a in GST capture assays. While the mutant proteins did exert ER-a repression activity in MCF-7 cells, the extent of repression was significantly less than that of the wtBRCA1 protein (Po0.001, two-tailed t-test), suggesting a partial disruption of BRCA1 function (Figure 12 ) (see Discussion).
Discussion
In this study, we have further characterized the structural determinants of the BRCA1 : ER-a interaction and their functional consequences. Specifically, we identified two separate contact points for ER-a on BRCA1, one within aa 1-100 and the other within aa 101-200 of BRCA1; and we found that aa 67-100 and 101-134 of BRCA1 are required for the interaction with ER-a. In particular, the BRCA1 RING domain (aa 24-64) was not required for binding to ER-a. A previous study revealed that in the context of the fulllength BRCA1 protein, a cancer-associated RINGdisrupting mutation (T300G ( 61 Cys-Gly)) abrogated the ability to inhibit ER-a activity, but did not block the binding to ER-a (Fan et al., 2001a) . These findings suggest that the RING domain is required for transcriptional repression of ER-a but does not contribute strongly to the physical interaction with ER-a. According to us, all of the binding to ER-a could be ascribed to BRCA1 aa 1-200, since aa 201-300 and 303-1863 of BRCA1 showed no binding activity. However, we note that a recent study of the BRCA1 : ER-a interaction identified an ER-a-binding site within aa 1-306 (consistent with our study) and a second site within aa 428-683 (which we did not observe) (Kawai et al., 2002) .
Our results suggest a partially overlapping set of structural determinants for three distinct functions of BRCA1: (1) the physical interaction with ER-a; (2) the repression of ER-a activity; and (3) the rescue of the repression of ER-a activity. As noted above, the in vitro and in vivo physical interaction involves portions of BRCA1 within aa 1-100 and 101-200; but either one of these truncated BRCA1 can interact with ER-a, suggesting two separate contact points. By themselves or when combined, BRCA1 1-100 and 101-200 can significantly repress ER-a activity; but the degree of repression is significantly less than that of the full-length BRCA1 protein, suggesting that regions of BRCA1 outside aa 1-200 are needed for maximal repression. A somewhat greater degree of binding to and repression of ER-a activity could be ascribed to BRCA1 1-100 than to BRCA1 101-200.
In prior studies, we had shown that BRCA1 aa 1-302 binds to ER-a but does not inhibit its activity (Fan et al., 2001a, b) . In contrast, BRCA1 1-302 and several longer C-terminal truncations (BRCA1 1-771 and 1-1313) acted as dominant inhibitors of the full-length BRCA1 protein with regard to its ability to repress ER-a activity. Unlike BRCA1 1-100 and 101-200, BRCA1 201-300 neither bound to nor repressed ER-a activity. Taken together, our data suggest that aa 201-300 of BRCA1 contains a 'rescue' or 'derepression' domain that can block the BRCA1 repression of ER-a, but only when it is recruited to ER-a by its attachment to an ER-abinding domain. While this hypothesis remains to be proven, our findings suggest that (1) the rescue function requires an additional portion of the BRCA1 protein not needed for binding; and (2) in the context of the fulllength wtBRCA1 protein, the rescue function is inactivated, while the binding and repression functions remain active.
Alternatively, it is possible that the rescue or depression activity ascribed to a domain within BRCA1 amino acids 201-300 is an artefact due to the overexpression of truncated BRCA1 proteins in the ER-a transcriptional assays. Such a domain, if it exists, may not be physiologically relevant if it is never exposed within the context of the full-length BRCA1 protein (see below). We do note that many or most cancerassociated BRCA1 mutations are insertion-deletion (frameshift) type mutations that cause C-terminal protein truncation; and these truncations occur throughout the BRCA1 protein (Miki et al., 1994; Gayther et al., 1995) . It is possible that some of these truncated proteins might 'derepress' ER-a by antagonizing the ability of the full-length BRCA1 encoded by the wildtype allele to inhibit ER-a. However, this idea is speculative, since we do not know the extent to which these truncated BRCA1 proteins are expressed under physiologic conditions. These studies have further delimited the BRCA1-binding domain(s) of ER-a, by identifying two regions that interact with BRCA1, aa 338-379 and aa 420-595, the first of which mediates a stronger interaction. Although the configuration of these regions is ligandsensitive, the protein interactions were observed in the absence and presence of E2, with only a modest reduction in binding for each site in the presence of E2. The primary interacting site appears to be aa 338-379 of ER-a, which usually showed a stronger interaction with BRCA1 in vitro. GST capture assays also suggest that aa 338-379 of ER-a can interact with both BRCA1 1-100 and BRCA1 101-200; while aa 420-595 of ER-a interacts only with BRCA1 1-100.
Examination of the BRCA1 amino-acid sequence within the first (and stronger) ER-a contact point (aa 67-100) revealed a leucine and isoleucine-rich region (aa 86-95) that occurred within a previously identified functional HIV Rev-type NES (Rodriguez and Henderson, 2000) and contained a nuclear receptor corepressorlike sequence, representing an extended helix compared to the nuclear receptor coactivator helix LxxLL (Perissi et al., 1999) . Thus, the corepressor consensus motif (Lxx(I/H)Ixxx(I/L)) differs from the sequence found in BRCA1 (LxxIIxxFxL) by the presence of one additional residue before the final leucine in the BRCA1 sequence. Studies utilizing different L/I-A substitutions revealed that a triple mutation (AxxAAxxFxL) strongly inhibited the ability of BRCA1 1-100 to bind, associate with, and repress ER-a. On the other hand, BRCA1 1-100 proteins harboring two other mutations (AxxIIxxFxL) and (LxxAAxxFxL) had a significantly smaller effect on repression and had little or no effect on in vivo association with or in vitro binding to ER-a.
In the context of the full-length BRCA1 protein, the triple mutation (but not the single and double mutations) significantly diminished the binding to and association with ER-a; and the triple mutation virtually abrogated the repression of ER-a. The other two mutants retained most of their ER-a binding, association, and repression activity. However, they were somewhat less efficient than wtBRCA1 at repressing ER-a activity, indicating that the mutations might still affect the BRCA1 : ER-a interaction or its consequences in a manner not detectable by our in vitro and in vivo assay systems.
A full-length BRCA1 protein with a double point mutation that inactivates the NES (AxxIAxxFxL) also failed to repress ER-a activity. This NES mutation significantly reduced but did not abrogate the ability of BRCA1 to associate with ER-a in vivo. The leucine and isoleucine residues within the NES/corepressor-like motif of BRCA1 are highly conserved evolutionarily (see Table 1 ). Taken together, these data suggest that a helicoid region of BRCA1 involving aa 86-95 contributes to the binding to and repression of ER-a. Interestingly, the triple mutation (within BRCA1 1-100 or full-length BRCA1) and the NES mutation virtually abolished the ability of BRCA1 to inhibit ERa; but the mutant proteins retained some ability (20-35%) to bind to or associate with ER-a. These findings suggest that loss of BRCA1 repression of ER-a activity does not require complete dissociation from ER-a. Alternatively, the residual binding of full-length mutant BRCA1 to ER-a could reflect a contribution from outside of the NES/corepressor-like motif (e.g., from a domain within aa 101-200).
A model structure for the BRCA1 : ER-a complex was prepared based on published structures for the BRCA1 N-terminus (aa 1-103) and the ER-a LBD (Figure 11 ). This model does not take into account the second ER-a-binding site within BRCA1 (aa 101-200), since we do not have structural information on this portion of the BRCA1 protein. This model suggests a mode of BRCA1 : ER-a interaction involving paired antiparallel a-helices. It also suggests a smaller interaction involving aa 420-595 of ER-a with the RING domain of BRCA1, but the major interaction involves the third helix of BRCA1 (aa 80-96) and the a-helix of ER-a aa 338-379. A further understanding of the structural basis of the BRCA1 : ER-a interaction and its consequences will require experimental validation of the proposed molecular model. Interestingly, this model predicted the presence of two tumor-associated single point mutations at the BRCA1 : ER-a interface, L63T and I89T. We did not necessarily expect these individual mutations to block the binding to ER-a, because: (1) they are only single amino-acid mutations on a broadly interacting surface; and (2) one other single point mutation (L86A) (called mutant 3 in the manuscript) and a double point mutation (I 89,90AA) (called mutant 2 in the paper) did not abrogate the binding. However, another double mutant (NES mutant) and a triple mutant (mutant 1) did inhibit binding and abrogate the BRCA1 repression. While the L63F and I89T mutations had little or no effect on the in vitro BRCA1 : ER-a interaction, they were significantly weaker than wtBRCA1 in repression of ER-a activity. Thus, while the point mutations do not affect binding (at least as determined using GST capture assays), they do partly disrupt BRCA1 function, consistent with being tumor-associated mutations. It is possible that these mutations affect the BRCA1 : ER-a interaction in another way or affect secondary interactions required for full repression.
The N-terminus of BRCA1 also interacts with BARD1 (BRCA1-associated RING domain 1); and the BRCA1:BARD1 RING domain dimer exhibits a ubiquitin protein ligase activity that may contribute to BRCA1 tumor suppressor activity (Hashizume et al., 2001; Brzovic et al., 2001; Morris et al., 2002) . This interaction involves the central RING motif and adjoining portion of BRCA1 (first 100 aa or so). Thus, it has been found that BRCA1 aa 8-22 and aa 81-96 (which includes the NES/corepressor-like sequences) form antiparallel a-helices that flank the central RING motif (Brzovic et al., 2001) . The corresponding regions of BARD1 form a similar type structure, which then heterodimerizes with BRCA1 as a four-bundle helix. Interestingly, several of the BRCA1 residues identified as being particularly important for hydrophobic interactions that determine the specificity of the BRCA1 : ER-a interaction (e.g., L-82, L-86, I-89, A-92, and L-95) were also identified as potentially important in the BRCA1 : ER-a interaction based on binding/ association assays, repression assays, and/or molecular modeling. As noted above, the RING motif itself is not required for BRCA1 binding to ER-a but is required for repression of ER-a activity (this study and Fan et al., 2001a) . Whether and how BARD1 may modulate the BRCA1 : ER-a interaction remains to be determined.
Materials and methods
Cell lines and culture
Human breast cancer (MCF-7 and HCC1937) and prostate cancer (DU-145) cell lines used in this study were obtained from the American Type Culture Collection (Manassas, VA, USA) and cultured as described before (Fan et al., 1998; Xiong et al., 2003) . Briefly, the cells were grown in Dulbecco modified Eagle's medium (DMEM) supplemented with 5% (v/v) fetal calf serum, L-glutamine (5 mM), nonessential amino acids (5 mM), penicillin (100 U/ml), and streptomycin (100 mg/ml) (all obtained from BioWhittaker, Walkersville, MD, USA).
Expression vectors and reporters
The wild-type BRCA1 expression vector (wtBRCA1) was created by cloning the BRCA1 cDNA into the pcDNA3 vector (Invitrogen) using artificially engineered 5 0 HindIII and 3 0 NotI sites (Fan et al., 1998) . cDNAs for BRCA1 1-302, 34-302, 67-302, 167-302, and 303-1863 were constructed by PCR cloning and inserted into the pcDNA3 vector. cDNAs for BRCA1 1-100, 101-200, and 201-300 were created by PCR cloning and inserted into the pCMV-Tag2B vector (Stratagene). The pCMV-Tag2B vector allows expression of the encoded BRCA1 protein with an N-terminal FLAG sequence (Fan et al., 2001b) . BRCA1 1-100 point mutants 1, 2, and 3 (see Table 1 and text) were constructed from the wtBRCA1 1-100 cDNA (in plasmid pCMV-Tag2B) using the QuikChange SiteDirected Mutagenesis Kit (Stratagene, Catalog # 200518) . Expression plasmids encoding full-length BRCA1 (BRCA1 1-1863) with point mutations 1, 2, and 3 and with two different tumor-associated BRCA1 mutations (L63F and I89 T) (see Table 1 ) were created by site-directed mutagenesis of wtBRCA1 within the pcDNA3 vector, using the QuikChange Site-Directed Mutagenesis Kit. An expression plasmid encoding a full-length BRCA1 protein with a double point mutation within the nuclear export sequence (BRCA1-NES mutant) was generously provided by Dr Brian R Henderson (Westmead Institute for Cancer Research, University of Sydney, Westmead Millennium Institute, New South Wales, Australia) (Rodriguez and Henderson, 2000) .
The ER-a expression vector pCMV-ER-a was used to express ER-a. The GST-ER-a plasmids have been described earlier (Fan et al., 2001a) . Additional plasmids to express GST-ER 338-379 and GST-ER 380-419 were constructed by PCR cloning of the appropriate segments of ER-a and insertion into the pGEX-5X-3 vector. The estrogen-responsive reporter ERE-TK-Luc is composed of the vitellogenin A2 estrogen-responsive enhancer (ERE) controlling a minimal thymidine kinase promoter (TK81) and luciferase, in plasmid pGL2 (Henttu et al., 1997) . Assays of ER-a transcriptional activity utilizing the ERE-TK-Luc reporter are described below.
Assays of E2-dependent transcriptional activity
Subconfluent proliferating cells in 24-well dishes were incubated overnight with 0.25 mg of each indicated vector in serumfree DMEM containing Lipofectaminet (Life Technologies). The total transfected DNA was kept constant by addition of the appropriate control vectors. The cells were washed, incubated in phenolphthalein-free DMEM containing 5% charcoal-stripped serum (obtained from the Tissue Culture core facility of the Lombardi Cancer Center) (0.2 ml/ well)717b-estradiol (E2, 1 mM) for 24 h, and harvested for luciferase assays. To control for transfection efficiency, plasmid pRSV-b-gal was cotransfected to allow normalization of luciferase values to b-galactosidase activity in the same sample. Values are means7s.e.m.'s of four replicate wells and are representative of two or more independent experiments.
IP
To study the association of different truncated or mutant BRCA1 proteins with ER-a, proliferating cells at about 80% of confluence in 100-mm plastic dishes were transfected overnight with the desired expression plasmids (10 mg of plasmid DNA/dish), using Lipofectaminet. Cells lacking endogenous ER-a (HCC1937) were cotransfected with a wild-type ER-a expression plasmid (pCMV-ER-a). The cells were washed and postincubated with fresh complete culture medium for 24 h to allow gene expression. The cells were then harvested; and whole-cell extracts were prepared as described before, using RIPA buffer (Fan et al., 2001a (Fan et al., , 2002 . Each IP was carried out using 2 mg of antibody and 500 mg of cell extract protein. The extracts were incubated overnight at 4 o C with anti-FLAG mouse monoclonal M2 (Sigma Chemical Co.) (for FLAG-tagged BRCA1 proteins), a combination of anti-BRCA1 mouse monoclonals (Ab-1 þ Ab-2 þ Ab-3, Oncogene Research Products) (for untagged BRCA1 proteins), or anti-ER-a H184 (rabbit polyclonal IgG, Santa Cruz Biotechnology, sc-7207). The precipitated proteins were collected using protein anti-FLAG affinity resin (Sigma) or protein A/G agarose (Santa Cruz), respectively. After low-speed centrifugation to remove the supernatants, the resin or agarose was washed with phosphate-buffered saline (PBS), collected in boiling Laemmli sample buffer, and subjected to SDS-PAGE and Western blotting (see below).
Western blotting
Equal aliquots of total protein (50 mg per lane) were electrophoresed on a 4-12% SDS-polyacrylamide gradient gel, transferred to nitrocellulose membranes (Millipore), and blotted using primary antibodies directed against FLAG (M2, mouse monoclonal, Sigma, 1 : 500 dilution), BRCA1 (C-20, rabbit polyclonal, Santa Cruz Biotechnology, 1 : 200), ER-a (F10, mouse monoclonal, Santa Cruz, sc-8002, 1 : 500 dilution), or a-actin (I-19, goat polyclonal, Santa Cruz, 1 : 500). Methodologic details are provided elsewhere (Fan et al., 1998 (Fan et al., , 2001a (Fan et al., , 2002 . The blotted proteins were visualized using the enhanced chemiluminescence system (ECL), with colored markers (BioRad) as molecular size standards.
GST capture assays
GST bead assays were performed essentially as described earlier (Fan et al., 2001a (Fan et al., , 2002 .
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S-methionine-labeled proteins were prepared by in vitro transcription, using the T7 promoter of pcDNA3 or the T3 promoter of pCMV-Tag2B. In vitro transcription and translation (IVT) and translation were carried out using the TNT-coupled rabbit reticulocyte lysate system (Promega), according to the manufacturer's instructions. The GST-ER fusion proteins were generated from cDNAs cloned into the p-GEX vector, expressed in Escherichia coli, and purified by affinity chromatography (Webb et al., 1998) . Labeled proteins were incubated with GST protein (negative control) or GST fusion proteins for 4 h at 41C, recovered using GSH agarose beads, eluted in boiling sample buffer, and analyzed by SDS-PAGE autoradiography. In all GST capture assays, the IVT input lanes show 10% of the protein used in the GST capture assays. The GST-ER fusion proteins were visualized by Western blotting, using anti-GST mouse monoclonal antibody 27-4577-01 (Amersham Pharmacia Biotech, 1 : 5000). Additional details relevant to specific experiments are provided in the text or figure legends.
Immunofluorescence staining DU-145 cells were cultured in eight-well Lab-Tek chamber slides (Nunc) in 1.5 ml of complete culture medium per well. Subconfluent proliferating cells were transfected overnight with the indicated expression vector (0.5 mg plasmid DNA/ well) using Lipofectaminet, washed, and postincubated in fresh medium for 24 h to allow gene expression. The cells were then washed with PBS, fixed in methanol for 10 min at room temperature, and then rinsed twice with PBS. The cells were then blocked with 1% goat serum and 2% bovine serum albumin in PBS at room temperature for 1 h; incubated with anti-FLAG monoclonal M2 (Sigma, 1 : 500 dilution) for 1 h; rinsed four times; and incubated with secondary antibody (goat anti-mouse IgG conjugated to Alexa Fluor 488 green (Molecular Probes, 1 : 1000 dilution) for 40 min. The cells were then rinsed four times (10 min each) with PBS and mounted in Vectashield mounting medium with 4 0 ,6-diamidino-2-phenylindole (DAPI, blue) (Vector Laboratories). They were then examined and photographed using a Nikon confocal laser fluorescence inverted microscope.
Statistical methods
Where appropriate, statistical comparisons were made using the two-tailed Student's t-test.
Three-dimensional (3D) molecular modeling of BRCA1 : ER-a complex
The 3D coordinates of BRCA1 1-103 (1JM7) (Brzovic et al., 2001 ) and the dimeric ER-a LBD (1A52) (Tanenbaum et al., 1998) structures were obtained from RCSB protein data bank. A total of 1000 model structures of the BRCA1/ER-a complex per cycle were calculated using the Global RAnge Molecular Matching (GRAMM) methodology (Katchalski-Katzir et al., 1992; Vakser et al., 1999) using the high-or low-resolution generic docking parameters.
The model complex structures were visualized and analysed with the MOLMOL program, MOLecule analysis and MOLecule display, v. 2k.2 (Koradi et al., 1996) . The complex structures that are consistent with the truncation and mutational studies on BRCA1 and ER-a reported in this article, and have low intermolecular energy by GRAMM were selected using in-house structure analysis programs. The complex structure depicted in this article is one of the structures that is most consistent with our biological data and that helps us to visualize a possible arrangement of the two proteins in the complex. However, detailed molecular interactions between BRCA1 and ER-a needs to be verified by experimental methods such as NMR solution spectroscopy or crystallography.
